Epstein-Barr Virus Infections Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Epstein-Barr Virus Infection / EBV Infections / EBV Infection / Epstein-Barr viral infections

IndicationStatusPhase
DBCOND0029759 (Epstein-Barr Virus Infections)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03258567Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasTreatment